Latest Top Pharmaceutical Companies in Japan NewsRSS

06:56 EDT 22nd April 2018 | BioPortfolio

Takeda sweetens offer for rival Shire to £42.8bn

Japanese pharma group’s latest proposal includes higher cash component

Shire turns down Takeda, Allergan toys with buy

Shire has rejected Takedaâs acquisition proposals saying the offers âundervalueâ its pipeline and potential for growth.

Takeda sweetens bid for Shire to £42.8bn

Japanese drugmaker also increases the cash component of the offer

Shire rejects US$63 billion Takeda bid as Allergan drops pursuit

Japan's Takeda Pharmaceutical is in negotiations with Shire after making a third takeover bid worth around US$61 billion that was rejected by the London-listed rare diseases drugmaker. FILE PHOTO: Takeda Pharmaceutical's signboard is seen on its headquarters building in Tokyo, Japan January 30, 2018.

Vaxart Announces $5 Million Inavir® Revenue Milestone

2017 Net Sales of Inavir® in Japan Exceeded ¥20 Billion, Triggering USD $5 Million Milestone Payment Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced today that it received notification from Daiichi Sankyo Co., Ltd, that sales of Inavir®, a s...

Fast-Growing Shire PLC Had Pharmaceutical Rivals in a Takeover Frenzy

Drugmaker Shire PLC has become the subject of topsy-turvy takeover interest, drawing suitors to one of the few remaining biotechs with rapidly rising sales and a stock price that hasn't soared in recent months. Japan's Takeda Pharmaceutical Co.

UPDATE: Takeda Comes Back to the Table, Shire Acquisition Bid Continues to Twist and Turn

Takeda Pharmaceutical has come back to the bargaining table with a juicier bid for Shire. Yesterday, Takeda’s $60 billion-plus bid for Shire took an odd turn late yesterday when Dublin, Ireland-based Allergan was reported to be in talks with Shire as well. However, by the end of the day, Allergan...

Shire rejects £42.4bn Takeda offer as Allergan rules itself out

Shares in Irish drugmaker yo-yo as US group says it may also bid, then pulls out

Allergan will not bid for Shire

Allergan announced it will not make an offer for Shire.The company will continue to evaluate its potential strategic actions, according to a press release.Allergan will not bid for Shire plc, the company announced. Source: ShutterstockIn an earlier release, Allergan responded to media speculation regarding a possible offer by saying it would announce its intentions before the May 17 deadline under...

Allergan considers bid for Shire

Allergan is considering a possible offer for Shire and is evaluating a range of potential strategic actions, the company announced in a press release.No offer has been made, and there is no certainty an offer will be made, the company said in response to media speculation.Allergan must announce its intention to make an offer or not make an offer by May 17 under the Takeover Code.Allergan is consid...

Bidding war looms over Shire after £42.4bn Takeda offer rejected

Shares in Irish drugs group jump as Allergan says it is also considering move

Takeover battle looms as Allergan considers bid for Shire

Botox maker’s interest comes after Irish drugmaker rejects bid by Japan’s Takeda

Astellas sells Agensys facilities to Gilead

Ownership of the California sites will be transferred to Gilead's Kite unit, which has a nearby plant for the production of its CAR-T therapies.

Shire rejects £42.4bn takeover bid from Takeda

Stock and cash offer values Irish drugmaker at £46.50 a share

STAT Plus: Pharmalittle: Shire rejects latest Takeda offer; Greek parliament ends Novartis bribery probe

The Greek parliament ended a probe into allegations that 10 senior politicians accepted millions of euros in bribes from Novartis.

Shire rejects £42.4bn takeover from Japan’s Takeda

Rival drugmakers remain in talks about potential deal following latest rebuff

Takeda makes £42.4bn bid for Shire

Stock and cash offer values Irish drugmaker at £46.50 a share

Shire Rejects Takeda Takeover Bids

Shire said today its board has rejected at least two takeover proposals by Takeda Pharmaceutical, but both companies have confirmed that they remain in talks about a possible acquisition. Shire’s board turned down Takeda’s initial approximately £41 billion ($58.4 billion) takeover offer, which would have left Shire shareholders owning 50% of the combined company—and a third proposal...

Shire rejects $62B offer from Takeda, while Allergan weighs bid

The Irish pharma has spurned three offers from the Japanese drugmaker; and now, Allergan confirms it is considering an offer as well. 

UPDATED: Shire Rejects Takeda’s $60 Billion Acquisition Bid and Allergan Reportedly In Talks with...

Takeda Pharmaceutical has made an official bid to acquire London’s Shire for about $60 billion. And in breaking news, Shire rejected the bid, saying it undervalued the company.

Acute Myeloid Leukaemia:KOL Insight [Report Updated: 01022018] Prices from USD $8495

How will four newly approved therapies transform treatment of AML?For decades, there were no approved treatments for acute myeloid leukaemia AML other than chemotherapies. The past year has witnessed the approval of four new therapies for AML; Novartis' Rydapt, Celgene/Agios' Idhifa, Jazz Pharma's Vyxeos and Pfizer's Mylotarg. How are these agents faring on the market so far and will more personal...

Astellas Volunteers Spread Cheer to Patients Battling Cancer

SOURCE: Astellas DESCRIPTION:Being away from families and friends during the holidays can be difficult. For a person battling cancer and their loved ones – this can be especially challenging.  To help brighten the day of these patients and their families, Astellas employees wrote inspirational messages on note cards and decorated them. These note cards were put into 2,000 care packages assemble...

Shire/Takeda: faith healers

To back the bid, investors must believe it can cut costs and promote faster growth

STAT Plus: Pharmalittle: Shire sells cancer biz as Takeda circles; FDA does about-face on Alkermes drug

Shire is selling its oncology business to unlisted French drug maker Servier, while Takeda may soon make a bid for Shire.

Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate from Astellas

Company expanding pipeline of novel treatments for cardiovascular disease Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has entered an

Quick Search


review and buy Top Pharmaceutical Companies in Japan market research data and corporate reports here